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The developmental and epileptic encephalopathies (DEE) are the most severe group of
epilepsies. Recently, NEXMIF mutations have been shown to cause a DEE in females,
characterized by myoclonic–atonic epilepsy and recurrent nonconvulsive status. Here
we used advanced neuroimaging techniques in a patient with a novel NEXMIF de novo
mutation presenting with recurrent absence status with eyelid myoclonia, to reveal brain
structural and functional changes that can bring the clinical phenotype to alteration within
specific brain networks. Indeed, the alterations found in the patient involved the visual
pericalcarine cortex and the middle frontal gyrus, regions that have been demonstrated
to be a core feature in epilepsy phenotypes with visual sensitivity and eyelid myoclonia
with absences.
Keywords: NEXMIF, non convulsive status epilepticus, developmental and epileptic encephalopathy, epilepsy,
eyelid myoclonia with absences, fMRI
INTRODUCTION
The developmental and epileptic encephalopathies (DEEs) are the most severe group of epilepsies
in which frequent epileptic activity, in addition to the underlying etiology, contributes to
developmental impairment, with onset typically in infancy or childhood (1). At least 50%
of the DEEs have a genetic cause (2), and there is significant etiological overlap with other
neurodevelopmental disorders such as intellectual disability (ID) and autism spectrum disorder (3).
The Neurite EXtension and MIgration Factor gene (NEXMIF), previously called KIAA2022
(OMIM 300524), is an X-linked gene thought to play an important role in early brain development
(4–7). Pathogenic NEXMIF variants were first identified in males with non-syndromic X-linked
ID with poor or absent speech, subtle dysmorphic features, and sometimes epilepsy (8, 9).
Subsequently, affected females have been described (10–14) and recently a large multicentric study
outlined the epilepsy phenotype of affected females (15) which is consistent with a generalized
DEE characterized by myoclonic–atonic epilepsy overlapping with eyelid myoclonia with absence.
Notably a considerable proportion of affected females present prolonged seizures characterized by
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absence status with eyelid myoclonia (15, 16). We report a female
patient with a de novo NEXMIF pathogenic variant and recurrent
prolonged episodes of absence status with eyelid myoclonia. In
order to evaluate the consequences ofNEXMIFmutation at brain
structural and functional MRI level (17) two different studies
were carried out comparing the patient with respect to patients
with genetic generalized epilepsy (GGE; formerly idiopathic) and
healthy controls (HC).
PATIENT AND METHODS
The patient is a 28-year-old woman, with a drug-resistant
epilepsy starting at the age of 9 years with recurrent
episodes of prolonged non-convulsive status epilepticus (NCSE)
characterized by mydriasis, eyelid myoclonia and reduced
responsiveness to environmental stimuli with a frequency of
1–2 episodes/month. She was born pre-term (8th gestational
month) from a dichorionic diamniotic twin pregnancy, from
unrelated parents. Family history is unremarkable for epilepsy,
febrile seizures, and any other neurological condition. Her
developmental milestones were slightly delayed (she started
walking at 16 months and talking at 24 months). She afterwards
achieved borderline intellectual functioning (full-scale IQ 75
at the age of 24 years; WAIS) with difficulties in visuo-
spatial information processing and dyspraxia. The patient also
presented night terrors and enuresis until late adolescence. Her
neurological examination is unremarkable.
During NCSE, which may last up to 48 h, the patient first
complains of an epigastric discomfort, followed by headache
and subsequent clouding of consciousness when she becomes
progressivelymore unaware and detached from the environment.
During this phase, the patient has mydriasis and presents
subcontinuous eye-blinking. EEGs recorded during NCSE show
a continuous, diffuse, spike- and poly-spike and wave-discharge,
worsened by eye closure, hyperventilation and by intermittent
photic stimulation (Supplementary Figure 1). Characteristically
eye closure induces the paroxysmal discharges while these tend
to reduce or disappear when the patient is asked to open her
eyes/stare or to perform a mental task. Beyond these episodes
the patient’s EEG background activity appears normal, with only
occasional diffuse sharp waves, mainly elicited by eye closure.
Various anti-seizure medications (ASM) in numerous
combinations were tried without achieving substantial benefit.
She was first started on valproic acid, with clonazepam, and then
switched to topiramate because of lack of efficacy. Lamotrigine,
lacosamide, zonisamide, acetazolamide and ethosuximide were
ineffective or even detrimental. A vagal nerve stimulator was
implanted at the age of 25 years. At the time of this report, the
patient is on valproate (1,000mg), lamotrigine (150mg) and
brivaracetam (150mg) but continues to have recurrent NCSE
even if more rarely than in the past.
Extensive metabolic and endocrinological screening showed
no significant abnormalities except for secondary amenorrhea.
Liver and renal functions are normal, and no alterations were
found on abdominal ultrasound and echocardiography. Brain
structural MRI shows no abnormality.
Genetic Testing
A NGS exome sequencing was performed on genomic DNA
from the patient and her parents by using the Nextera Rapid
Capture Exomes kit and massively parallel sequencing (Illumina,
PE 2 × 150). Sequence mapping and variant calling were
performed using GATK software. Variants with certain or
probable pathogenic significance based on ACMG guidelines
were validated by Sanger sequencing.
The analysis revealed the presence of the chrX-73962221-
C- (GRCh37/hg19 assembly) variant in the NEXMIF
gene (c.2171delG, NM_001008537, p.S724MfsTer5) in
the heterozygous state. This variant is not reported in the
international registry of mutations published in the literature
(ClinVar) and is not present in the human polymorphism
databases (GnomAD, dbSNP147). The segregation analysis
showed the variant was de novo. The variant is predicted to
have pathogenic consequences according to ACMG criteria.
Additionally, at the protein level, the p.S574MfsTer5 variant
affects an evolutionarily highly conserved amino acid according
to in-silico tool GERP++ score 5.73. The variant is predicted to
cause a non-sense mediated decay and a premature truncation
with effect on protein function according to in-silico tools (Sift
score 0.858, Provean score−5.16 and Mutation taster).
Structural MRI Study
For comparison, 20 matched females with GGE and 20 matched
healthy females (HC) were recruited. The mean age of the GGE
group was 22.74 years old; that of the HC group was 28.45
(p > 0.05). All GGE patients had normal structural brain MRI on
conventional diagnostic protocol at 3 Tesla and no intellectual
disability (full-scale IQ > 80) or psychiatric comorbidities. Since
the patient was under treatment with valproate at the time of the
study, and valproate has been demonstrated to be associated with
subcortical atrophy and posterior cortical thinning (18, 19), we
included in the GGE control group only females (selected from
our MRI research database) that were already on treatment with
valproate at the time of the MR imaging study. The HC had no
history of neurological diseases or past valproate use, or family
history of epilepsy, and had normal structural neuroimaging.
Moreover, all controls had a normal EEG, since they were
recruited for previous EEG-fMRI co-registration study protocols
by our group. The details of MRI acquisition and post-processing
analyses are reported in Supplementary Material.
MRI Cortical Thickness and Subcortical Volume
Analyses
Scans were analyzed using a standardized image toolbox
(Freesurfer, version 5.0) (20), quality assurance (outlier detection
based on inter quartile of 1.5 standard deviations along with
visual inspection of segmentations), and statistical methods.
Visual inspections of subcortical and cortical segmentations were
conducted following standardized ENIGMA protocols (http://
enigma.usc.edu), used in prior genetic studies of brain structure
(21, 22), large-scale case-control studies of epilepsy (23) and
neuropsychiatric illnesses (24, 25).
Statistical analyses were performed using SPSS software
26.0 (IBM, Chicago, IL). To compare cortical measures
Frontiers in Neurology | www.frontiersin.org 2 September 2021 | Volume 12 | Article 722664
Cioclu et al. NEXMIF Encephalopathy
between the proband and each group, we conducted the
Crawford’s modified independent sample t-test using the
program singlims.exe (https://homepages.abdn.ac.uk/j.crawford/
pages/dept): this tests whether a patient’s score is significantly
below controls, thus providing a point estimate of the
abnormality of the patient’s score (i.e., it estimates the
percentage of the control population exhibiting a lower
score), accompanying confidence limits on this quantity,
and results with point and interval estimates of effect sizes
(26). Percentile calculation for each variable was performed
to inspect case’s distribution values in comparison to HC
and GGE.
TABLE 1 | Significant differences in subcortical volumes and cortical thickness in the patient compared to GGE sample.
GGE Significance test Estimated percentage of the
GGE population obtaining a
lower score than the case
Estimated effect size
Mean Standard deviation Proband t p Point 95% CI Point 95% CI
Subcortical structures volumes (mm3)
R thalamus 6479.69 704.78 5236.7 −1.721 0.05 5.07 0.68 14.77 −1.764 −2.463 −1.046
Cortical thickness (mm)
L caudal middle frontal 2.50 0.22 1.938 −2.528 0.02 1.02 0.02 4.88 −2.564 −3.51 −1.656
L lingual 2.02 0.13 1.77 −1.952 0.05 3.29 0.28 11.06 −2 −2.759 −1.223
R caudal middle frontal 2.47 0.24 1.847 −2.673 0.01 0.75 0.01 3.89 −2.739 −3.7 −1.763
R pars triangularis 2.58 0.26 1.992 −2.215 0.03 1.96 0.09 7.75 −2.269 −3.1 −1.421
R precentral 2.31 0.15 1.926 −2.537 0.02 1 0.02 4.82 −2.6 −3.522 −1.662
R superior temporal 2.89 0.20 2.431 −2.196 0.04 2.03 0.1 7.96 −2.25 −3.076 −1.407
p-values are written in bold.
TABLE 2 | Significant difference in subcortical volumes and cortical thickness in proband compared to healthy controls.
Healthy controls sample Significance test Estimated percentage of the HC
population obtaining a lower
score than the case
Estimated effect size
Mean Standard deviation Proband t p Point 95% CI Point 95% CI
Subcortical structures volumes (mm3)
R thalamus 6785.84 624.26 5,237 −2.423 0.02 1.27 0.03 5.74 -2.482 −3.372 −1.577
L caudal 3624.45 448.02 2,614 −2.2 0.04 2.01 0.1 7.91 -2.254 −3.081 −1.411
R amygdala 2028.33 216.60 1,545 −2.187 0.04 2.07 0.1 8.06 -2.241 −3.064 −1.401
Cortical thickness (mm)
L caudal middle frontal 2.50 0.17 1.938 −3.11 0.005 0.28 0 1.85 -3.187 −4.277 −2.084
L fusiform 2.71 0.13 2.398 −2.327 0.03 1.55 0.05 6.6 -2.385 −3.247 −1.506
L inferior parietal 2.36 0.13 1.923 −3.228 0.004 0.22 0 1.5 -3.308 −4.432 −2.169
L lateral occipital 2.22 0.15 1.849 −2.649 0.01 0.79 0.01 4.05 -2.714 −3.668 −1.745
L lingual 2.02 0.11 1.77 −2.342 0.03 1.51 0.05 6.46 -2.4 −3.266 −1.517
L middle temporal 2.88 0.17 2.397 −2.813 0.01 0.55 0 3.1 -2.882 −3.884 −1.866
L pars opercularis 2.47 0.17 2.104 −2.067 0.05 2.63 0.18 9.5 -2.118 −2.908 −1.31
L postcentral 2.01 0.13 1.697 −2.402 0.02 1.33 0.04 5.91 -2.462 −3.345 −1.562
L superior temporal 2.90 0.20 2.391 −2.62 0.01 0.84 0.01 4.24 -2.684 −3.63 −1.723
L supramarginal 2.46 0.16 2.116 −2.135 0.04 2.3 0.13 8.66 -2.188 −2.996 −1.361
R caudal middle frontal 2.52 0.18 1.847 −3.904 <0.001 0.04 0 0.39 -4 −5.329 −2.659
R lateral occipital 2.18 0.11 1.92 −2.307 0.03 1.62 0.06 6.8 -2.36 −3.22 −1.491
R pars triangularis 2.49 0.19 1.992 −2.711 0.01 0.69 0.008 3.66 -2.778 −3.75 −1.792
R peri calcarine 1.64 0.12 1.356 −2.484 0.02 1.12 0.02 5.23 -2.545 −3.452 −1.623
R precentral 2.39 0.15 1.926 −3.058 0.006 0.32 0.001 2.041 -3.133 −4.207 −2.045
R superior temporal 2.99 0.16 2.431 −3.416 0.002 0.14 0 1.05 -3.5 −4.681 −2.306
p-values are written in bold.
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FIGURE 1 | Morphometric and Functional results. (A) surface brain templates depicting regions of cortical thinning in the proband compared to HC (top images) and
GGE (bottom images). Brain statistics were displayed using the ggseg and ggseg3d packages integrated into the software R environment using the Desikan-Killiany
cortical atlas (28). (B) Percentile distribution of cortical thickness for the left and caudal middle frontal gyri in the case compared to controls and GGE; see text for
details. (C) BOLD maps related to the eye closure conditions in the patient compared to controls (left images) and GGE (right images). Results are overlaid into the
MNI152 template as provided by the MRIcroGL toolbox.
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Functional MRI Study
Patients (the proband and GGE) and controls were investigated
by means of a task-related EEG-fMRI protocol in order to
elucidate brain activity related to eye-closure condition. In this
second study the GGE population consisted of 14 patients
(13 females, mean age = 24.9 years, mean age of epilepsy
onset= 12.6 years). The healthy control group consisted of 16
subjects (12 females, mean age = 28 years). The experimental
protocol and EEG-fMRI data pre-processing and analysis
have been extensively described previously by our group (see
Supplementary Materials) (27).
RESULTS
Cortical Thickness and Subcortical
Volumes
Subcortical structural comparison between the proband and HC
group showed volume reduction in the right thalamus (p= 0.02),
right amygdala (p = 0.04), and left caudate (p = 0.04). Cortical
thickness analyses showed that the patient had reduced cortical
thickness in several brain regions in comparison toHC, including
left (p= 0.005) and right caudal middle frontal gyrus (p< 0.001),
left fusiform (p= 0.03) and left inferior parietal gyrus (p= 0.004),
left (p= 0.01), and right (p= 0.03) lateral occipital gyrus, and left
lingual gyrus (p= 0.03; Table 1).
Subcortical structural comparison between proband and GGE
group showed that the case had volume reduction in the right
thalamus (p = 0.05). Cortical thickness analyses showed that the
patient had reduced cortical thickness in several brain regions in
comparison to GGE, including left (p = 0.02) and right caudal
middle frontal gyrus (p = 0.01), and the left lingual gyrus (p =
0.05; Table 2).
Figure 1A shows surface brain template depicting regions of
cortical thinning in the proband compared to HC and GGE.
Percentile distribution confirmed that in the patient, right and
left caudal middle frontal gyri cortical thickness had values
below IQR and extreme values in comparison to both HC
and GGE (Figure 1B). Supplementary Table 1 show percentile
distribution for the patient in comparison to all HC and GGE.
Brain Correlates of Eye-Closure
A total of 13 voluntary eyes closure conditions were recorded.
Compared to HC, the patient demonstrated increased BOLD
signal changes at the left cuneus. When compared to GGE,
a diffuse network appeared encompassing the left precentral
gyrus, the left basal ganglia, the bilateral superior temporal
gyrus, the right inferior frontal gyrus and the pons (Figure 1C;
Supplementary Table 2). No significant BOLD changes were
observed in the opposite comparisons (i.e., HC and GGE vs.
the proband).
DISCUSSION
NEXMIF plays an important role in neural circuit formation
during development (4–8). Knockdown of NEXMIF leads to
dramatic impairment in neurite outgrowth, with a particular
impact on the lengths of dendrites and axons (9). To our
knowledge, this is the first study to attempt to identify
whether pathogenicNEXMIF variants induce alterations in brain
structure or in functional networks in humans. In summary,
compared to other populations, the studied patient shows a
thinning of the prefrontal cortex and in particular of the middle
frontal gyrus, of the temporal lobe cortex (including the fusiform
gyrus) and of pericalcarine visual cortex. Consistently, these
areas have shown functional alterations (increase of BOLD signal
compared to controls) in the condition of eye closure: this finding
is of interest because this pattern of functional activation was
previously documented in patients with a clinical phenotype
characterized by eyelid myoclonia and absences (27). In fact,
the patient, although not having the clinical phenotype typical
of Jeavons syndrome, demonstrated prolonged NCSE episodes
characterized by absences with eyelid myoclonia.
Here the use of advanced neuroimaging techniques in
a specific genetic phenotype revealed brain structural and
functional changes that can bring the clinical phenotype
to alteration within specific brain networks, and especially
in networks physiologically involved in several visuomotor
function, including the motor control of eye-closure and eye-
movements, and attention to visual targets. Notably, it is not
possible to determine whether the observed morphometric
alterations are ascribable to the dysfunction of the NEXMIF
gene primarily, or what role has the repetition of prolonged
NCSE on these regions. Indeed, this study needs replication
in both males and females carrying pathogenic gene mutations
in NEXMIF gene to come to the conclusion that the observed
network alterations are gene specific, or mutation mediated
effects, or a feature of the association of epileptic seizure
phenotype of eyelid myoclonia with absences. To note, it is
unlikely that the observed structural/functional MRI changes are
result of single gene defect but may be the consequence of effects
mediated by more than one gene involved in the development
of visuomotor networks. Of course, the results obtained should
be considered with caution and reflect patient-specific brain
changes. That said, the study has identified consistent alterations
in cortical/subcortical morphometry and functional imaging thus
providing a link between the genetic alteration and in vivo
brain functioning/morphology.
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